Skip to main content
. Author manuscript; available in PMC: 2010 Mar 15.
Published in final edited form as: Cancer Res. 2009 Mar 10;69(6):2384–2392. doi: 10.1158/0008-5472.CAN-08-3953

Table 1.

In vitro activities of DSA1-DSA9 and imatinib against Abl, c-Src and Hck. All assays were performed in triplicate or quadruplicate.

graphic file with name nihms93695f5.jpg IC50 (nM)
R1 R2 Abl c-Src Hck
graphic file with name nihms93695t1.jpg graphic file with name nihms93695t2.jpg
DSA1		 10 ± 3 4.6 ± 1.5 10 ± 3
graphic file with name nihms93695t3.jpg
DSA2		 14 ± 3 4.6 ± 0.9 13 ± 3
graphic file with name nihms93695t4.jpg
DSA3		 2.9 ± 0.5 <1 1.8 ± 0.3
graphic file with name nihms93695t5.jpg
DSA4		 18 ± 3 6.4 ± 2.2 8.4 ± 1.6
graphic file with name nihms93695t6.jpg
DSA5		 7.2 ± 1.3 3.4 + 1.0 6.5 ± 0.3
graphic file with name nihms93695t7.jpg
DSA6		 7.6 ± 1.4 3.0 ± 0.6 5.9 ± 1.0
graphic file with name nihms93695t8.jpg graphic file with name nihms93695t9.jpg
DSA7		 1.5 ± 0.1 <1 2.2 ± 0.2
graphic file with name nihms93695t10.jpg
DSA8		 2.7 ± 0.3 2.8 ± 0.2 6.6 ± 2.3
graphic file with name nihms93695t11.jpg
DSA9		 7.7 ± 3.1 8.3 ± 2.1 10 ± 2
graphic file with name nihms93695t12.jpg
imatinib		 11 ± 3 >10000 5600